Dyax and Cubist Sign Deal for DX-88 Surgical Indications
By Helen Scrutton
Pharma Deals Review: Vol 2008 Issue 94 (Table of Contents)
Published: 24 Apr-2008
DOI: 10.3833/pdr.v2008.i94.191 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
This article discusses Dyax and Cubist Pharmaceuticals’ recent deal for Dyax’s DX-88 (ecallantide), a Phase II product for the prevention of blood loss during surgery in North America and Europe...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS